Senior executives from Morgan Stanley (NYSE:MS), now said to be a key consultant to Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), called Valeant a “house of cards,” in an e-mail to Allergan, Inc. (NYSE:AGN) management saying “your investors should not want to take their stock.”
MS Called Valeant "House of Cards" When Pitching Allergan
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.